Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics, Inc. Appoints Nadine Greiner as Chief Human Resources Officer

08/12/2021 | 04:04pm EDT

4D Molecular Therapeutics, Inc. announced the appointment of Nadine Greiner, Ph.D. as Chief Human Resources Officer. Ms. Greiner has served as head of human resources for 25 years at organizations including California Pacific Medical Center, the Palo Alto Medical Foundation at Sutter Health, The Institute on Aging, and Bank of America.


© S&P Capital IQ 2021
All news about 4D MOLECULAR THERAPEUTICS, INC.
10/134D MOLECULAR THERAPEUTICS INC. : Other Events (form 8-K)
AQ
10/114D MOLECULAR THERAPEUTICS' : 4D-125 Drug Shows Potential in Eye Disease Trial
MT
10/104D MOLECULAR THERAPEUTICS : ASRS 2021 Annual Meeting – 4D-125 for XLRP Phase 1/2 Cli..
PU
10/104D MOLECULAR THERAPEUTICS : Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cli..
AQ
10/104D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cl..
CI
10/06Health Care Stocks Trade Lower Premarket Wednesday
MT
10/064D MOLECULAR THERAPEUTICS : Obtains FDA Clearance for Phase 1/2 Trial of Wet Age-Related M..
MT
10/064D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-710, an A101..
AQ
10/064D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-150, a Dual-..
AQ
10/064D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual..
CI
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 16,9 M - -
Net income 2021 -71,0 M - -
Net cash 2021 196 M - -
P/E ratio 2021 -12,6x
Yield 2021 -
Capitalization 874 M 874 M -
EV / Sales 2021 40,0x
EV / Sales 2022 256x
Nbr of Employees 104
Free-Float 77,1%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | FDMT | US35104E1001 | MarketScreener
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 32,39 $
Average target price 50,00 $
Spread / Average Target 54,4%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Operating & Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-21.86%874
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455